PMID- 35574402
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent 
      Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of 
      Cisplatin.
PG  - 842281
LID - 10.3389/fonc.2022.842281 [doi]
LID - 842281
AB  - BACKGROUND: We conducted this study to evaluate if a reduced cumulative dose of 
      induction and concurrent cisplatin conferred similar favorable outcomes when 
      compared to trial NPC-0501. METHODS: Newly diagnosed nasopharyngeal carcinoma 
      (NPC) with stage III-IVA were prospectively recruited from January 2015 to 
      September 2019. Induction chemotherapy (IC) consisted of cisplatin 80mg/m(2) on 
      day 1 and capecitabine 1000mg/m(2) twice daily from day 1 to 14 every 3 weeks for 
      3 cycles followed by concurrent chemoradiotherapy (CCRT) with 2 cycles of 
      cisplatin 100mg/m(2) given every 3 weeks. Tumor response was evaluated according 
      to RECIST v1.1. Acute and late adverse events (AEs) were graded with CTCAE v4.0 
      and Late Radiation Morbidity Scoring of the RTOG, respectively. RESULTS: 135 
      patients were recruited. At 16 weeks after CCRT, all 130 patients who completed 
      the entire course of radiotherapy (RT) had a complete response upon final 
      assessment. With a median follow-up of 36.2 months, 22 treatment failures and 8 
      deaths were observed. The 3-year progression-free survival, overall survival, 
      locoregional recurrence-free survival, and distant recurrence-free survival were 
      83.7%, 94.1%, 94.1%, and 85.9%, respectively. Our survival data outcomes were 
      similar to those reported in the cisplatin and capecitabine (PX) induction arm of 
      the 0501 trial. 103 patients (76.3%) reported acute grade 3-4 AEs. Two patients 
      (1.5%) had late grade 3-4 complications, numerically fewer than those reported in 
      the NPC-0501 trial. CONCLUSIONS: Induction PX and concurrent cisplatin with a 
      reduced cumulative cisplatin dose yield survival outcomes comparable to those 
      reported in the NPC-0501 trial with excellent tolerability. Therefore, a reduced 
      cumulative dose of cisplatin is a promising treatment scheme for nasopharyngeal 
      carcinoma.
CI  - Copyright (c) 2022 Xu, Yang, Ng, Helali, Lee, Ma, Liu, Li, Shen, Huang, Zha, Zhou, 
      Lee and Chen.
FAU - Xu, Zhiyuan
AU  - Xu Z
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
AD  - Clinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, 
      Shenzhen, China.
FAU - Yang, Li
AU  - Yang L
AD  - Clinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, 
      Shenzhen, China.
FAU - Ng, Wai-Tong
AU  - Ng WT
AD  - Clinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, 
      Shenzhen, China.
AD  - Department of Clinical Oncology, The University of Hong Kong, Hong Kong, Hong 
      Kong SAR, China.
FAU - Helali, Aya El
AU  - Helali AE
AD  - Clinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, 
      Shenzhen, China.
AD  - Department of Clinical Oncology, The University of Hong Kong, Hong Kong, Hong 
      Kong SAR, China.
FAU - Lee, Victor Ho-Fun
AU  - Lee VH
AD  - Clinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, 
      Shenzhen, China.
AD  - Department of Clinical Oncology, The University of Hong Kong, Hong Kong, Hong 
      Kong SAR, China.
FAU - Ma, Lingyu
AU  - Ma L
AD  - Clinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, 
      Shenzhen, China.
FAU - Liu, Qin
AU  - Liu Q
AD  - Clinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, 
      Shenzhen, China.
FAU - Li, Jishi
AU  - Li J
AD  - Clinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, 
      Shenzhen, China.
FAU - Shen, Lin
AU  - Shen L
AD  - Clinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, 
      Shenzhen, China.
FAU - Huang, Jijie
AU  - Huang J
AD  - Clinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, 
      Shenzhen, China.
FAU - Zha, Jiandong
AU  - Zha J
AD  - Clinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, 
      Shenzhen, China.
FAU - Zhou, Cheng
AU  - Zhou C
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Lee, Anne W M
AU  - Lee AWM
AD  - Clinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, 
      Shenzhen, China.
AD  - Department of Clinical Oncology, The University of Hong Kong, Hong Kong, Hong 
      Kong SAR, China.
FAU - Chen, Longhua
AU  - Chen L
AD  - Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220427
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9092977
OTO - NOTNLM
OT  - capecitabine
OT  - cisplatin
OT  - induction chemotherapy
OT  - nasopharyngeal carcinoma
OT  - progression-free survival
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/05/17 06:00
MHDA- 2022/05/17 06:01
PMCR- 2022/01/01
CRDT- 2022/05/16 04:42
PHST- 2021/12/23 00:00 [received]
PHST- 2022/03/25 00:00 [accepted]
PHST- 2022/05/16 04:42 [entrez]
PHST- 2022/05/17 06:00 [pubmed]
PHST- 2022/05/17 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.842281 [doi]
PST - epublish
SO  - Front Oncol. 2022 Apr 27;12:842281. doi: 10.3389/fonc.2022.842281. eCollection 
      2022.